571 related articles for article (PubMed ID: 31607486)
1. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
[TBL] [Abstract][Full Text] [Related]
2. Decreased total psoas muscle area after neoadjuvant therapy is a predictor of increased mortality in patients undergoing oesophageal cancer resection.
Yassaie SS; Keane C; French SJH; Al-Herz FAJ; Young MK; Gordon AC
ANZ J Surg; 2019 May; 89(5):515-519. PubMed ID: 30959566
[TBL] [Abstract][Full Text] [Related]
3. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
[TBL] [Abstract][Full Text] [Related]
5. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
[TBL] [Abstract][Full Text] [Related]
6. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
[TBL] [Abstract][Full Text] [Related]
9. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
[TBL] [Abstract][Full Text] [Related]
10. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
[TBL] [Abstract][Full Text] [Related]
11. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
[TBL] [Abstract][Full Text] [Related]
12. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
[TBL] [Abstract][Full Text] [Related]
13. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation.
Esser H; Resch T; Pamminger M; Mutschlechner B; Troppmair J; Riedmann M; Gassner E; Maglione M; Margreiter C; Boesmueller C; Oberhuber R; Weissenbacher A; Cardini B; Finkenstedt A; Zoller H; Tilg H; Öfner D; Schneeberger S
Transplantation; 2019 Dec; 103(12):2506-2514. PubMed ID: 30985737
[TBL] [Abstract][Full Text] [Related]
15. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
[TBL] [Abstract][Full Text] [Related]
16. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative psoas muscle index, a surrogate for sarcopenia; as a predictor of post-esophagectomy complications.
Yunrong T; Jin WW; Mahendran HA; Koon YB; Jahit S; Kamaruddin MA; Anuar N; Daud NAM
Dis Esophagus; 2024 Apr; 37(4):. PubMed ID: 38163959
[TBL] [Abstract][Full Text] [Related]
18. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis.
Wang P; Wang S; Li X; Lin G; Ma Y; Xiao R; Li H; Qiu M; Yang F
Int J Surg; 2022 Jan; 97():106206. PubMed ID: 34990833
[TBL] [Abstract][Full Text] [Related]
20. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer.
Mayanagi S; Tsubosa Y; Omae K; Niihara M; Uchida T; Tsushima T; Yokota T; Sato H; Naito T; Yasui H
Ann Surg Oncol; 2017 Nov; 24(12):3741-3747. PubMed ID: 28861809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
